Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.99
-2.2%		$51.86
$37.80
▼
$61.69
$103.14B0.364.65 million shs2.92 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
-1.98%+1.00%-1.41%+2.24%+37.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.99
-2.2%		$51.86
$37.80
▼
$61.69
$103.14B0.364.65 million shs2.92 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
-1.98%+1.00%-1.41%+2.24%+37.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.10
Hold$53.003.94% Upside

Current Analyst Ratings Breakdown

Latest GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
7/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/24/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral
7/17/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
7/6/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeReduce ➝ Hold
6/11/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
6/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.39$5.78 per share8.82$10.32 per share4.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.2015.949.923.0414.56%43.23%11.60%10/28/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.793.51%-7.86%55.94%N/A

Latest GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45153.36%8/14/20268/14/202610/8/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.81
0.82
0.52

Institutional Ownership

CompanyInstitutional Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%

Insider Ownership

CompanyInsider Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable

Recent News About These Companies

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
 |  cnbc.comhttps://www.cnbc.com/2026/08/11/mmr-vaccine-trump-wants-to-split-childhood-shot-up.html
Parashmoni Deori joins GSK India as Corporate Communications Manager
August 11 at 8:00 AM  |  exchange4media.comE
GSK slides Monday, underperforms market
August 11 at 8:00 AM  |  marketwatch.comhttps://www.marketwatch.com/data-news/gsk-slides-monday-underperforms-market-652d219e-a40c72b56f1e
GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of "Hold" by Brokerages
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943638
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gsk-plc-sponsored-adr-nysegsk-given-average-rating-of-hold-by-brokerages-2026-08-06/
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
August 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GSK/pressreleases/3630552/bernstein-sticks-to-their-buy-rating-for-glaxosmithkline-gsk/
GSK India first-quarter profit rises on steady vaccine demand
August 3, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/gsk-india-first-quarter-profit-rises-steady-vaccine-demand-2026-08-03/
GSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation Therapeutics
August 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-lse-gsk-opens-cambridge-061535052.html
GSK (NYSE:GSK) Cut to Hold at Wall Street Zen
August 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30933471
GSK (NYSE:GSK) Lowered to "Hold" Rating by Wall Street Zen
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gsk-nysegsk-lowered-to-hold-rating-by-wall-street-zen-2026-08-01/
GSK to move R&D to Cambridge in £400m UK investment
July 30, 2026  |  bmmagazine.co.ukB
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
July 30, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/gsk-relation-therapeutics-sign-up-110-million-ai-drug-discovery-deal-2026-07-30/
GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-plc-gsk-q2-2026-010332221.html
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-beats-q2-earnings-revenue-155200606.html
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
July 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2963565/gsk-beats-q2-earnings-revenue-estimates-announces-cost-saving-plan?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2963565
GSK PLC Sponsored ADR (NYSE:GSK) Announces Quarterly Dividend of $0.45
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gsk-plc-sponsored-adr-nysegsk-announces-quarterly-dividend-of-045-2026-07-29/
GSK unveils cost-saving plan to fund R&D, research HQ move
July 28, 2026  |  fiercebiotech.comF
GSK plc (GSK) Q2 2026 Earnings Call Transcript
July 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926597-gsk-plc-gsk-q2-2026-earnings-call-transcript
GSK heads to Cambridge with long-awaited positive vibes
July 28, 2026  |  theguardian.comhttps://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes
The David Rubenstein Show: GSK CEO Emma Walmsley
July 28, 2026  |  bloomberg.comhttps://www.bloomberg.com/news/videos/2020-11-19/the-david-rubenstein-show-gsk-ceo-emma-walmsley-video
GSK Stock Rises as $2.52 Billion Savings Plan Funds Pipeline
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-stock-rises-2-52-195100747.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK stock logo

GSK NYSE:GSK

$50.99 -1.17 (-2.24%)
Closing price 03:59 PM Eastern
Extended Trading
$51.18 +0.20 (+0.38%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas